Self-Expanding Valves Outperform Balloon-Expandable Systems in Hemodynamics for Small Valve-in-Valve TAVR: 3-Year LYTEN Trial Results

MedXY Editorial Team•Mar 3, 2026•Cardiology

Self-expanding valves (SEV) demonstrated significantly superior hemodynamic performance compared to balloon-expandable valves (BEV) at 3-year follow-up in patients undergoing valve-in-valve transcatheter aortic valve replacement (ViV-TAVR) for failed small surgical bioprostheses.
The rate of intended valve performance was markedly higher in the SEV group (82.4%) than in the BEV group (27.6%).
Despite hemodynamic differences, clinical outcomes—including mortality, stroke, and heart failure-related hospitalizations—were similar between both valve types at the 3-year mark.
Functional status and quality of life improved significantly and similarly in both patient cohorts.

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Self-expanding valves (SEV) demonstrated significantly superior hemodynamic performance compared to balloon-expandable valves (BEV) at 3-year follow-up in patients undergoing valve-in-valve transcatheter aortic valve replacement (ViV-TAVR) for failed small surgical bioprostheses.
The rate of intended valve performance was markedly higher in the SEV group (82.4%) than in the BEV group (27.6%).
Despite hemodynamic differences, clinical outcomes—including mortality, stroke, and heart failure-related hospitalizations—were similar between both valve types at the 3-year mark.
Functional status and quality of life improved significantly and similarly in both patient cohorts.